GlassScriptPhysician profile
Dennis Lowenthal
NPI 1528050374
$2,452.96
in general payments reported to CMS, 2019-2025
47 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $349 · 2021: $357 · 2022: $277 · 2023: $199 · 2024: $141 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.46 |
| Education | $133.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $252.23 | 2019-2025 | Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $239.86 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $191.63 | 2019-2021 | |
| Amgen INC. | $178.01 | 2019-2022 | |
| Astellas Pharma US INC | $142.31 | 2019-2023 | |
| Janssen Biotech, INC. | $128.99 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Medtronic Minimed, INC. | $112.03 | 2020 | |
| Lilly USA, LLC | $97.01 | 2019-2022 | |
| Abbvie INC. | $89.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $78.03 | 2019-2021 | |
| Seagen INC. | $67.19 | 2020-2022 | |
| Genentech USA, INC. | $64.57 | 2019 | |
| Celgene Corporation | $59.51 | 2019-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $55.48 | 2019-2025 | Fruzaqla |
| Genmab U.S., INC. | $54.83 | 2021-2023 | Epkinly |
Show all 45 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Lowenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.